Affiliation:
1. Department of Dermatology, Mayo Clinic School of Graduate Medical Education, Rochester, Minnesota;
2. Division of Dermatologic Surgery, Department of Dermatology, Mayo Clinic, Rochester, Minnesota
Abstract
BACKGROUND
Although advances have been made in the understanding of recurrence patterns in dermatofibrosarcoma protuberans, the current understanding of disease-specific mortality after surgical management is limited.
OBJECTIVE
To understand disease-specific mortality rates associated with dermatofibrosarcoma protuberans treated with wide local excision (WLE) versus Mohs micrographic surgery (MMS).
MATERIALS AND METHODS
A systematic literature search was conducted on March 6, 2023, to identify patients treated with MMS or WLE for dermatofibrosarcoma protuberans.
RESULTS
A total of 136 studies met inclusion criteria. Overall, the disease-specific mortality rate was not significantly different after treatment with MMS (0.7%, confidence interval [CI] 0.1–1.2, p: 0.016) versus WLE (0.9%, CI 0.6–1.2, p < .001). For recurrent tumors, the MMS treatment group had a statistically significantly lower disease-specific mortality rate (1.0%, CI 0.0–2.0, p 0.046) compared with the WLE treatment group (3.5%, CI 2.0–5.1, p < .001). The mean follow-up for all studies was 57.6 months.
CONCLUSION AND RELEVANCE
The authors' meta-analysis suggests there is no substantial difference in disease-specific mortality between MMS and WLE in patients with dermatofibrosarcoma protuberans, except in the case of recurrent tumors, where MMS seems to confer a survival advantage.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献